Related Experiment Videos
DNA methylation and cancer therapy: new developments and expectations
1Cancer Epigenetics Laboratory, Spanish National Cancer Centre (CNIO) Madrid, Spain. mesteller@cnio.es
Current Opinion in Oncology
|December 21, 2004
Summary
Cancer is an epigenetic disease, with aberrant DNA methylation inactivating tumor-suppressor genes. DNA-demethylating agents are promising chemotherapeutics, with new, less toxic drugs and improved detection methods advancing cancer treatment.
Area of Science:
- Oncology
- Epigenetics
- Pharmacology
Background:
- Cancer is increasingly recognized as an epigenetic disease, characterized by aberrant DNA methylation patterns.
- CpG-island hypermethylation in promoter regions is a hallmark, leading to tumor-suppressor gene inactivation.
- DNA-demethylating agents are a promising class of chemotherapeutic drugs targeting these epigenetic alterations.
Purpose of the Study:
- To review recent advancements in DNA-demethylating agents for cancer therapy.
- To highlight novel compounds, mechanistic insights, and clinical progress in epigenetic cancer treatment.
Main Methods:
- Review of recent scientific literature on DNA-demethylating agents.
- Analysis of new drug development, molecular mechanisms, and clinical trial outcomes.
- Evaluation of advancements in analytical techniques for drug effect measurement.
Main Results:
- Development of less toxic and orally available DNA-demethylating compounds (e.g., procaine, zebularine).
- Enhanced understanding of drug mechanisms at both gene-specific and genomic levels.
- Improved clinical sample analysis techniques (e.g., high-performance capillary electrophoresis) and FDA approval of 5-azacytidine for myelodysplastic syndrome.
Conclusions:
- Epigenetic drugs, particularly DNA-demethylating agents, represent a significant advancement in cancer therapy.
- Initial success in hematological malignancies is expected to extend to solid tumors.
- Further research is needed to develop more specific agents, understand their effects, and explore combinations with other epigenetic drugs and chemotherapy.